News

ODI Pharma AB (“ODI” or “the Company”) hereby publishes its half-yearly report for the period October – December 2019. The report is available as an attached...

ODI Pharma AB (“ODI Pharma” or “the Company”) hereby announce that Aphria Inc. (“Aphria”), the Company’s supplier of medical cannabis, has received its Europ...

Stockholm, 20.01.2020. As communicated earlier today, ODI Pharma AB's (“ODI Pharma” or “Company”) recently completed new share issue has been partially regis...

Stockholm, 20.01.2020. ODI Pharma AB's ("ODI Pharma" or "Company") recently completed new share issue was significantly oversubscribed and the Company will t...

The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was completed on the 30th o...

ODI Pharma AB (“ODI Pharma” or “the Company”), a medical cannabis finished product producer, today announces that the Company has been approved for listing o...

Zug/Switzerland, August 2nd, 2019 - The board of ODI Pharma Schweiz AG announces that its operations will be consolidated shortly under a Swedish holding com...